Know Cancer

forgot password

A Phase II Study to Evaluate the Efficacy of RAD001 in Metastatic Non-clear Cell Renal Cell Carcinoma

Phase 2
18 Years
Not Enrolling
Renal Cell Carcinoma

Thank you

Trial Information

A Phase II Study to Evaluate the Efficacy of RAD001 in Metastatic Non-clear Cell Renal Cell Carcinoma

Inclusion Criteria:

1. Histologically or cytologically confirmed non-clear cell renal cell carcinoma
(papillary, chromophobe, collecting duct, oncocytic subtype, sarcomatoid mainly)

2. Subjects with metastatic legion

3. Subjects aged 18 years or older

4. Subjects whose ECOG performance status is 0 or 1

5. Subjects who have laboratory value below; Hematology

- Neutrophil >= 1.5 x 109/L

- Platelet >= 75 x 109/L

- Hemoglobin >= 9 g/dL Liver function tests

- Total bilirubin ≤ 1.5 xULN

- AST, ALT ≤ 2.5 xULN

- Alkaline phosphatase ≤ 2.5 xULN Renal function tests

- Creatinine clearance >= 30 mL/min

6. Subjects who understand and provide a written informed consent

Exclusion Criteria:

1. Subjects who have been administered an mTOR inhibitor

2. Pregnant or nursing women, and women of childbearing potential must use appropriate
contraception for the study period and the result of their pregnancy test performed
within 14 days before enrollment must be negative

3. Subjects who participated in a clinical study using the study medication within 30
days before randomization

4. Subjects with clinically uncontrolled central nervous system (CNS) metastasis

5. Subjects with life expectancy of less than 3 months

6. Subjects with interstitial pulmonary disease

7. Subjects whose QTc interval is prolonged (QTc > 450 msec for male or > 470 msec for

8. Other serious diseases or medical conditions Heart disease unstable despite treatment
History of myocardial infarction within six months before the study History of
serious neurological or psychological disorder including dementia or seizure Active
peptic ulcer which cannot be controlled by a drug

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free survival

Outcome Time Frame:

2 months, 4 months, 6 months

Safety Issue:



South Korea: Korea Food and Drug Administration (KFDA)

Study ID:




Start Date:

January 2009

Completion Date:

December 2012

Related Keywords:

  • Renal Cell Carcinoma
  • Renal cell carcinoma
  • Non-clear cell
  • RAD001
  • Metastatic, non-clear cell, renal cell carcinoma
  • Carcinoma
  • Carcinoma, Renal Cell